← All countries · Evidence Explorer · Previous: Venezuela

Evidence at a glance

• Traditional knowledge: historical and contemporary Guyana studies document community use and cultural meanings of plants; this is not proof of treatment benefit.
• Diabetes: bitter melon has a small short-term trial signal, but pooled randomized evidence found no statistically significant glycemic benefit. Moringa studies conflict across formulations and populations.
• Cancer: a small soursop leaf-extract trial measured laboratory cytotoxicity of participants’ serum, not shrinkage of tumors, recurrence or survival.
• Safety: concentrated bitter melon can compound glucose-lowering medicines; soursop raises neurologic concerns; high-bioavailability curcumin may injure the liver or alter drug exposure; improperly processed bitter cassava can release cyanide.
• Other chronic diseases: respiratory, neurologic, autoimmune, cardiovascular and mental-health conditions deserve serious attention, including clear documentation when botanical evidence is absent.

Scope and method: This is a selective, source-linked historical and clinical evidence chapter. Most human intervention trials discussed took place outside Guyana. Sources checked November 13, 2026; source publication dates are specified separately.

Living knowledge: a country is not a single medical tradition

Guyana has distinct Indigenous, Afro-Guyanese, Indo-Guyanese and other communities, with histories of plant knowledge, food, spirituality, trade and clinical care that cannot be reduced to one list of “bush medicines.” Cultural use deserves accurate attribution, but it answers a different question from whether a formulation improves a patient-important outcome.

An original 1978/79 ethnomedical botany paper by Gary Mihalik documented informant reports and plant specimens, identifying 25 medicinal plants by names and uses. The Library of Congress archival annotation was checked; the original full paper was not accessed, so detailed preparation claims are not made.

A 2023 original study with Taruma and Wapichan plant knowledge holders explored smartphone-based documentation and plant identification under pandemic travel restrictions. A 2024 Taruma language and plants paper examined plant naming and shared histories; a separate 2024 Guianas ethnography explored relationships with plants and their meanings in particular communities. These are valuable Indigenous scholarship and ethnographic sources, not clinical trials. The 2023 abstract was available; full text access was limited and group-specific knowledge is not generalized to all Guyanese.

Pakuri: a Guyana-based diabetes survey, not a treatment trial

Boston and colleagues (published May 8, 2019) studied knowledge and use of traditional medicine for type 2 diabetes among 318 residents of Pakuri (St. Cuthbert’s Mission). Their cross-sectional methods described community and individual consent. Diabetes was reported in 40.3% of this study sample, and more than half of affected respondents reported using traditional medicine. This is a selected sample—not Guyana’s national diabetes prevalence, nor the prevalence among all Indigenous peoples.

The researchers could document experiences and attitudes but did not randomize participants, compare equivalent treatment groups or show that herbs prevented kidney disease, heart disease or loss of glucose control. The journal abstract and methods summary were reviewed; full numerical adjustment and individual remedy preparation data were not independently verified. This distinction is essential for respecting local experience without promising an untested clinical result.

Carilla (bitter melon): a familiar food and an uncertain diabetes remedy

Guyanese reporting describes carilla, or Momordica charantia, as a bitter vegetable used in local cooking. Names elsewhere include bitter melon, bitter gourd and cerasee. A cooked serving and a concentrated leaf or seed preparation are very different exposures. The household tradition does not automatically match a trial product.

Fuangchan et al. (2011; PMID 21211558) conducted a four-week multicenter randomized double-blind active-control trial, assigning participants to bitter melon 500, 1,000 or 2,000 mg daily or metformin 1,000 mg daily. With 2,000 mg/day bitter melon, fructosamine decreased 10.2 μmol/L from baseline (95% CI −19.1 to −1.3); with metformin the decrease was 16.8 μmol/L (95% CI −31.2 to −2.4). Lower bitter melon doses had no clearly significant within-group fructosamine benefit. This is a short-term surrogate outcome, not evidence of fewer strokes, kidney failures or deaths.

A 2014 systematic review of four randomized trials (208 participants) found no statistically significant HbA1c benefit (weighted mean difference −0.13 percentage points, 95% CI −0.41 to 0.16) or fasting glucose benefit (2.23 mg/dL, 95% CI −14.91 to 19.37). A review is not an extra independent trial; some of the same studies appear in both sources. Small trials, variable products and uncertain bias preclude substituting bitter melon for diabetes treatment.

Memorial Sloan Kettering’s bitter-melon safety summary (updated May 23, 2025) describes potential gastrointestinal effects, serious isolated case reports, pregnancy concerns and additive low-blood-sugar risk with insulin or other diabetes drugs. Laboratory anticancer activity is not proof of effectiveness in cancer patients. A cervical-cancer study did not show improved natural-killer-cell activity; immune markers alone could not show cancer control even if they did change.

Moringa and cardiometabolic health: three studies, different answers

Moringa (Moringa oleifera) is used as food and in various commercial preparations, including in Guyana. The research concerns specific leaf preparations, not all food uses or extracts. A 2017 randomized placebo-controlled study in Thailand enrolled 32 treatment-naive adults with type 2 diabetes and tested 8 g/day of leaf capsules for four weeks. Fasting glucose and HbA1c did not significantly improve versus placebo. No adverse effects were reported during that limited follow-up; this cannot establish long-term safety.

In contrast, a Spanish double-blind trial, published December 24, 2021 in a 2022 journal volume, allocated 31 adults with prediabetes to 2,400 mg/day dry moringa leaf powder and 34 to placebo for 12 weeks. Changes in fasting glucose and HbA1c favored moringa, but other markers including studied microbiota, liver/kidney measures and appetite hormones did not show significant between-group improvement. This does not establish diabetes prevention or reduction in cardiovascular events.

A 2023 Nigerian trial allocated 40 adults with diabetes to four diets supplying 0, 20, 40 or 60 g/day of leaves for 14 days. After accounting for baseline values, the study did not find significant between-group metabolic differences; a within-group increase in triglycerides in one arm also cautions against choosing only favorable within-group comparisons. None of these trials was conducted in Guyana, and no study establishes cancer-treatment benefits from moringa.

Cancer: soursop is not a demonstrated cure

Soursop or graviola (Annona muricata) has a history as fruit and as leaves prepared for drinks. Fruit consumed as food differs from a concentrated leaf, root, bark or seed product. Indrawati et al. (2017; PMID 28582808) enrolled 30 adults after colorectal-cancer resection in a double-blind placebo-controlled trial; 28 completed, with 14 per arm. A specified leaf extract was given over eight weeks. Investigators examined nutrition and whether patients’ serum affected cultured cancer cells outside the body.

Even where the ex-vivo cell assay suggested greater cytotoxicity, the trial did not show that tumors within people shrank, recurrence fell or overall survival improved. The existing Soursop Evidence Explorer record discusses the same trial and safety data in depth; counting its mention here as a second trial would be misleading. Annonaceae compounds such as annonacin raise unresolved neuronal-toxicity concerns from observational and experimental work. An association with atypical parkinsonism is not definitive causation from ordinary fruit servings, and there is no established medicinal dose.

Turmeric, inflammation, neuropathy and drug interactions

Turmeric can be a culinary ingredient in Guyanese households, but dietary turmeric is not the same as grams of concentrated curcumin enhanced with piperine. The NCCIH turmeric review finds some early signals for osteoarthritis symptoms and certain fatty-liver markers, but no definitive benefit across formulations; liver injury has been reported with some high-bioavailability supplements.

A small formulation-specific oral-mucositis study suggests a supportive symptom benefit in cancer care, not anticancer action. A 16-person pharmacokinetic trial summarized in the Evidence Explorer found that high-dose curcumin, particularly with piperine, lowered exposure to endoxifen, an active tamoxifen metabolite. Recurrence or survival were not measured; a medicine-exposure concern is enough to justify pharmacist review. Similar caution applies to attempts to extrapolate small neuropathy studies to cancer prevention.

Cassava: cultural expertise and a neurologic safety lesson

An original 2019 anthropological study by Janette Bulkan described the central place of bitter cassava in Makushi and Akawaio food systems, including women’s knowledge and cultivation/processing practices. The study is about food security, culture and knowledge—not a clinical efficacy study. Proper preparation is part of expertise and deserves recognition.

At the same time, FAO technical guidance explains that insufficiently processed bitter cassava can release hydrogen cyanide from cyanogenic glycosides. A long-term clinical follow-up of konzo, a spastic neurologic syndrome associated with inadequate cassava processing in food-insecure settings, illustrates a real risk. That report was not a Guyana-specific outbreak, and properly processed cassava must not be conflated with toxic raw root. Cassava is food, not a treatment for neurologic disease.

Respiratory, autoimmune, neurologic and other chronic conditions

The Guyana Ministry of Health noncommunicable-disease programme includes hypertension, diabetes, cancers, chronic respiratory disease and mental health among its priorities. Yet this focused search did not verify rigorous Guyana-specific trials showing that household teas prevent COPD or asthma exacerbations, replace inhaled medicines, suppress autoimmune diseases such as lupus, or treat Parkinson’s disease. That is an evidence gap, not a reason to caricature cultural practices.

For cancer-related symptoms, some non-botanical integrative methods have better research than widely promoted “anticancer” teas. The SIO–ASCO pain guideline supports selected uses of acupuncture, massage and related supportive approaches; the 2024 ASCO–SIO fatigue guideline update recommends carefully adapted exercise, cognitive-behavioral interventions and mindfulness-based programs in appropriate settings. These are supportive-care outcomes, not evidence of tumor control. Applicability and access must be considered locally.

Practical safety checkpoints

• Identify the precise species, plant part, preparation, concentration and source; a vernacular name alone can be ambiguous.
• Review all diabetes medicines before using concentrated carilla/bitter-melon products; hypoglycemia can be dangerous.
• Discuss concentrated soursop and unexplained tremor, rigidity or other new neurologic symptoms. Its cancer benefit is unproven.
• Separate turmeric food use from high-dose curcumin/piperine: interactions with tamoxifen and rare liver injury are clinically relevant.
• Do not use raw or inadequately processed bitter cassava. Proper processing is a safety requirement, not a treatment protocol.
• Do not delay surgery, chemotherapy, endocrine therapy, insulin, prescribed inhalers or immune-modifying medicines because of laboratory or anecdotal herbal claims.

Questions for the care team

• Was the claimed benefit observed in randomized humans with my condition, or only in surveys, test tubes, animals, or biomarkers?
• Does the actual tested formulation match what I am using?
• Could it interact with insulin, chemotherapy, tamoxifen, anticoagulants, corticosteroids or other prescribed treatments?
• Are there liver, kidney, pregnancy, neurologic or nutrition concerns?
• How do we preserve a valued cultural practice while avoiding unsafe substitutions for effective care?

Original studies and guidance checked

• Mihalik, Guyanese ethnomedical botany (1978/79) — Library of Congress bibliographic annotation; original full paper not inspected.
• Holt et al., Indigenous plant documentation (2023); Taruma plant-language original study (2024) — cultural research.
• Boston et al., Pakuri diabetes survey (2019) — original Guyana cross-sectional study, abstract and methods summary.
• Fuangchan et al., bitter-melon randomized trial (2011); Yin et al., 2014 review — trials not double-counted.
• Taweerutchana et al., moringa T2D trial (2017); Gómez-Martínez et al., moringa prediabetes trial (2022 volume); Afiaenyi et al., moringa diabetes trial (2023).
• Indrawati et al., soursop randomized colorectal study (2017); existing Evidence Explorer appraisal.
• Hussaarts et al., curcumin and tamoxifen pharmacokinetics (2019); NCCIH turmeric safety.
• Bulkan, Makushi/Akawaio bitter cassava (2019); FAO cassava processing; original konzo follow-up.
• MSK bitter melon safety (updated May 23, 2025); NCI integrative-care principles; Guyana Ministry of Health NCD programme.

Sources checked: November 13, 2026. Original full text was inspected for the 2017 Thai moringa and 2021-published Spanish moringa studies. Several other studies were abstract-only, archived bibliographic references, or institutional summaries; therefore unverified methods, attrition, funding and confidence intervals were not inferred. This chapter is not a systematic review, a Guyana-wide prevalence survey or a personal fieldwork report.

Educational only. No plant here is an established cure for cancer. Natural products can interact with drugs, and laboratory or short-term biomarker findings must not be interpreted as evidence of tumor response, fewer recurrences or longer survival. Discuss possible treatments and supplements with the care team.

Country Explorer index · Evidence Explorer · Safety and interactions